146 related articles for article (PubMed ID: 15778081)
21. Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.
Scholl S; Krause C; Loncarevic IF; Müller R; Kunert C; Wedding U; Sayer HG; Clement JH; Höffken K
J Lab Clin Med; 2005 Jun; 145(6):295-304. PubMed ID: 15976757
[TBL] [Abstract][Full Text] [Related]
22. New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation.
Bao T; Smith BD; Karp JE
Clin Adv Hematol Oncol; 2005 Apr; 3(4):287-96, 302. PubMed ID: 16167001
[TBL] [Abstract][Full Text] [Related]
23. FLT3 tyrosine kinase as a target in acute leukemias.
Griffin JD
Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
[No Abstract] [Full Text] [Related]
24. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
Wang J; Wang T; Li S; Lin L; Gang Y
Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
[TBL] [Abstract][Full Text] [Related]
25. Acute leukemia.
Ganser A; Hoelzer D
Curr Opin Hematol; 1994 Jul; 1(4):248-55. PubMed ID: 9371290
[TBL] [Abstract][Full Text] [Related]
26. FLT3 mutations in childhood acute lymphoblastic leukemia at first relapse.
Wellmann S; Moderegger E; Zelmer A; Bettkober M; von Stackelberg A; Henze G; Seeger K
Leukemia; 2005 Mar; 19(3):467-8. PubMed ID: 15674414
[No Abstract] [Full Text] [Related]
27. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia.
Aleskog A; Höglund M; Pettersson J; Hermansson M; Larsson R; Lindhagen E
Leuk Res; 2005 Sep; 29(9):1079-81. PubMed ID: 16038735
[TBL] [Abstract][Full Text] [Related]
29. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Kim KT; Levis M; Small D
Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
[TBL] [Abstract][Full Text] [Related]
30. Rapid and sensitive detection of internal tandem duplication and activating loop mutations of FLT3.
Mills KI; Gilkes AF; Walsh V; Sweeney M; Gale R
Br J Haematol; 2005 Jul; 130(2):203-8. PubMed ID: 16029448
[TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type.
Chen W; Jones D; Medeiros LJ; Luthra R; Lin P
Br J Haematol; 2005 Sep; 130(5):726-8. PubMed ID: 16115128
[TBL] [Abstract][Full Text] [Related]
32. Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6.
Takahashi S; Harigae H; Ishii KK; Inomata M; Fujiwara T; Yokoyama H; Ishizawa K; Kameoka J; Licht JD; Sasaki T; Kaku M
Leuk Res; 2005 Aug; 29(8):893-9. PubMed ID: 15978940
[TBL] [Abstract][Full Text] [Related]
33. No correlation between trisomy 13 and FLT3 duplication in acute myeloid leukemia.
Powell H; Curtis A; Bown N; Taylor P
Cancer Genet Cytogenet; 2005 Jan; 156(1):92-3. PubMed ID: 15588866
[No Abstract] [Full Text] [Related]
34. Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories.
Schilsky RL; Dressler LM; Bucci D; Monovich L; Jewell S; Suster S; Caligiuri MA; Kantoff PW; Compton C
Clin Cancer Res; 2002 May; 8(5):943-8. PubMed ID: 12006505
[No Abstract] [Full Text] [Related]
35. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
36. Small molecule FLT3 tyrosine kinase inhibitors.
Levis M; Small D
Curr Pharm Des; 2004; 10(11):1183-93. PubMed ID: 15078134
[TBL] [Abstract][Full Text] [Related]
37. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
38. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias.
Paietta E; Ferrando AA; Neuberg D; Bennett JM; Racevskis J; Lazarus H; Dewald G; Rowe JM; Wiernik PH; Tallman MS; Look AT
Blood; 2004 Jul; 104(2):558-60. PubMed ID: 15044257
[TBL] [Abstract][Full Text] [Related]
39. Treatment of childhood acute myeloid leukemia.
ter Bals E; Kaspers GJ
Expert Rev Anticancer Ther; 2005 Oct; 5(5):917-29. PubMed ID: 16221060
[TBL] [Abstract][Full Text] [Related]
40. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]